Form DEFA14A Sensei Biotherapeutics,
Sensei Biotherapeutics, Inc. (SNSE)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
SNSE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNSE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNSE alerts
High impacting Sensei Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SNSE
News
- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) is now covered by analysts at Stephens. They set an "overweight" rating and a $5.00 price target on the stock.MarketBeat
- EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board MemberBusiness Wire
- Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingGlobeNewswire
SNSE
Earnings
- 5/9/24 - Miss
SNSE
Sec Filings
- 5/16/24 - Form 3
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- SNSE's page on the SEC website